JP2025509432A5 - - Google Patents

Info

Publication number
JP2025509432A5
JP2025509432A5 JP2024553843A JP2024553843A JP2025509432A5 JP 2025509432 A5 JP2025509432 A5 JP 2025509432A5 JP 2024553843 A JP2024553843 A JP 2024553843A JP 2024553843 A JP2024553843 A JP 2024553843A JP 2025509432 A5 JP2025509432 A5 JP 2025509432A5
Authority
JP
Japan
Prior art keywords
disorder
therapeutic combination
receptor agonist
receptor
combination according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024553843A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025509432A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/014926 external-priority patent/WO2023172701A2/en
Publication of JP2025509432A publication Critical patent/JP2025509432A/ja
Publication of JP2025509432A5 publication Critical patent/JP2025509432A5/ja
Pending legal-status Critical Current

Links

JP2024553843A 2022-03-09 2023-03-09 エンタクトゲン心理状態を設計および生成するための治療的組み合わせ、組成物、および方法 Pending JP2025509432A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263318369P 2022-03-09 2022-03-09
US63/318,369 2022-03-09
PCT/US2023/014926 WO2023172701A2 (en) 2022-03-09 2023-03-09 Therapeutic combinations, compositions, and methods for designing and producing entactogenic mindstates

Publications (2)

Publication Number Publication Date
JP2025509432A JP2025509432A (ja) 2025-04-11
JP2025509432A5 true JP2025509432A5 (cg-RX-API-DMAC7.html) 2026-03-17

Family

ID=87935763

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024553843A Pending JP2025509432A (ja) 2022-03-09 2023-03-09 エンタクトゲン心理状態を設計および生成するための治療的組み合わせ、組成物、および方法

Country Status (11)

Country Link
US (1) US20250177354A1 (cg-RX-API-DMAC7.html)
EP (1) EP4489649A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025509432A (cg-RX-API-DMAC7.html)
KR (1) KR20250011101A (cg-RX-API-DMAC7.html)
CN (1) CN119497589A (cg-RX-API-DMAC7.html)
AU (1) AU2023232712A1 (cg-RX-API-DMAC7.html)
CA (1) CA3245622A1 (cg-RX-API-DMAC7.html)
CR (1) CR20240417A (cg-RX-API-DMAC7.html)
IL (1) IL315512A (cg-RX-API-DMAC7.html)
MX (1) MX2024011043A (cg-RX-API-DMAC7.html)
WO (1) WO2023172701A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250145285A (ko) * 2024-03-28 2025-10-13 건국대학교 글로컬산학협력단 릴메니딘을 포함하는 정서장애의 예방, 개선 또는 치료용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721978D0 (en) * 1997-10-17 1997-12-17 Lilly Co Eli Treatment of depression
DE19938823A1 (de) * 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
CN101318020B (zh) * 2007-06-06 2011-09-28 四川科瑞德制药有限公司 抗焦虑或/和抗抑郁的药物组合物及用途
WO2014004676A1 (en) * 2012-06-26 2014-01-03 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors as neuroprotective agents in the cns
US12414936B2 (en) * 2017-02-09 2025-09-16 Caamtech, Inc. Compositions comprising a serotonergic tryptamine compound

Similar Documents

Publication Publication Date Title
RU2317817C2 (ru) Применение (1s,2r) энантиомера милнаципрана для получения лекарственного средства
Wichniak et al. Sleep and antidepressant treatment
KR100704319B1 (ko) 고선택성 노르에피네프린 재흡수 억제제 및 그의 이용 방법
JP2021519271A5 (cg-RX-API-DMAC7.html)
CN117693336A (zh) 抑郁症的治疗
JP2021519267A5 (cg-RX-API-DMAC7.html)
JP7245509B2 (ja) 吃音を治療するための融合ベンズアゼピン
JP2008531714A (ja) 不安障害の治療用及び/又は予防用の医薬組成物
JP2009531435A (ja) うつ病の治療用の新規な治療組み合わせ
US20180092916A1 (en) Methods of treating disease-induced ataxia and non-ataxic imbalance
JP2012526832A5 (cg-RX-API-DMAC7.html)
TW201906604A (zh) Nk-1 拮抗劑組合物及用於治療抑鬱症之方法
JP2025510942A5 (cg-RX-API-DMAC7.html)
JP2009500421A (ja) エスゾピクロン及び抗うつ薬の組み合わせ
EP4547250A1 (en) Methods and compositions relating to controlling psychedelic effects with serotonin receptor modulators
CN104884060A (zh) 治疗方案
Huynh et al. Fibromyalgia: Diagnosis and management for the primary healthcare provider
US20030087963A1 (en) Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
Elia Side effects of antidepressants
US20060217394A1 (en) Treatment of anhedonia
WO2009147831A1 (ja) 精神障害の治療方法および治療用医薬組成物
JP2023008912A5 (cg-RX-API-DMAC7.html)
Rizek et al. Management of Advanced Parkinson’s Disease
Roux et al. Medications and Sleep
Deka et al. Fluoxetine-induced blurring of vision: a rare ocular side effect.